{"DataElement":{"publicId":"2960478","version":"1","preferredName":"Nitrosourea Compound Preparative Regimen Administered Type","preferredDefinition":"A description of nitrosourea compound administered as part of the preparative regimen.","longName":"2960476v1.0:2960473v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2960476","version":"1","preferredName":"Nitrosourea Compound Preparative Regimen Administered","preferredDefinition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier._The chemotherapy and/or radiation given to blood, marrow or cord blood transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur._The act of having given something (e.g., a medication or test).","longName":"2960474v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2960474","version":"1","preferredName":"Nitrosourea Compound Preparative Regimen","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.:The chemotherapy and/or radiation given to bone marrow transplant patients prior to transplant to kill diseased cells and/or make space for healthy new marrow and/or suppress the immune system so graft rejection does not occur.","longName":"C699:C61155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Preparative Regimen","conceptCode":"C61155","definition":"The chemotherapy or radiation given prior to blood, marrow, cord blood transplant, or cell infusion to kill diseased cells and make space for the healthy new graft and/or suppress the immune system so rejection does not occur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-1307-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-1315-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for \"nitro\" No version needed. AK 9/6/13 Updated def for prep reg, no version needed. AK 12/20/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2960473","version":"1","preferredName":"Nitrosourea Compound Type","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas._Type; a subdivision of a particular kind of thing.","longName":"NIT_CMP_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Carmustine","valueDescription":"Carmustine","ValueMeaning":{"publicId":"2567422","version":"1","preferredName":"Carmustine","longName":"2567422","preferredDefinition":"A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12D5-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"Lomustine","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12E9-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"781A9DB0-12F3-EEF4-E040-BB89AD4369AF","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2960472","version":"1","preferredName":"Nitrosourea Compound Type","preferredDefinition":"A group of anticancer drugs that can cross the blood-brain barrier. Carmustine (BCNU) and lomustine (CCNU) are nitrosoureas.:Type; a subdivision of a particular kind of thing.","longName":"C699:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nitrosourea Compound","conceptCode":"C699","definition":"Any of a class of alkylating agents that contain both a nitroso group and a urea. They are lipophilic and can cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-12B0-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ONEDATA","dateModified":"2009-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-12C1-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"NYCHM","dateModified":"2012-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964872","version":"1","longName":"2000r1: Recipient Baseline Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"MaterialName:name","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What type of nitrosourea comp","type":"Preferred Question Text","description":"What type of nitrosourea compound was administered?","url":null,"context":"NHLBI"},{"name":"Nitrosourea","type":"Alternate Question Text","description":"Nitrosourea","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2960478","type":"BRIDG Mapping Path","description":"PerformedProcedure > DefinedProcedure > Product > MaterialName.name WHERE Product.typeCode = \"Nitrosourea\" AND DefinedProcedure > DefinedCompositeRelationship > DefiendActivity AND DefinedActivity.nameCode = \"Perform composite preparative regimen\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"781A9DB0-132E-EEF4-E040-BB89AD4369AF","latestVersionIndicator":"Yes","beginDate":"2009-11-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2009-11-11","modifiedBy":"ALEYR","dateModified":"2019-04-07","changeDescription":".Updated def for \"Nitro\", no version needed. AK 9/6/13 Updated def for prep reg, no version needed. AK 12/20/13 Added human readable def. System generated def displayed as alt def. No version needed. AK 10/16/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}